JP2022525013A5 - - Google Patents
Info
- Publication number
- JP2022525013A5 JP2022525013A5 JP2021552772A JP2021552772A JP2022525013A5 JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5 JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutically acceptable
- acceptable salt
- active against
- additional agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814316P | 2019-03-06 | 2019-03-06 | |
| US62/814,316 | 2019-03-06 | ||
| PCT/IB2020/051878 WO2020178767A1 (en) | 2019-03-06 | 2020-03-04 | Compounds useful in hiv therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525013A JP2022525013A (ja) | 2022-05-11 |
| JP2022525013A5 true JP2022525013A5 (cg-RX-API-DMAC7.html) | 2024-07-16 |
Family
ID=69845479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552772A Ceased JP2022525013A (ja) | 2019-03-06 | 2020-03-04 | Hiv療法において有用な化合物 |
Country Status (22)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL289925B2 (en) | 2019-07-27 | 2026-03-01 | Brii Biosciences Inc | A derivative of adenosine and a pharmaceutical preparation containing it |
| MX2022002897A (es) | 2019-09-11 | 2022-05-16 | Scripps Research Inst | Profarmacos antivirales y formulaciones de los mismos. |
| IL293566A (en) * | 2019-12-09 | 2022-08-01 | Viiv Healthcare Co | Pharmaceutical preparations containing Cabotgravir |
| KR102987126B1 (ko) * | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| CN116370479B (zh) * | 2020-12-30 | 2024-02-13 | 南方科技大学 | 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途 |
| AU2022211056A1 (en) * | 2021-01-25 | 2023-07-20 | Brii Biosciences, Inc. | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| KR20230132476A (ko) * | 2021-01-25 | 2023-09-15 | 브리 바이오사이언시스, 인크. | 아데노신 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2022182604A1 (en) * | 2021-02-23 | 2022-09-01 | Viiv Healthcare Company | Compounds useful in hiv treatment |
| EP4658663A2 (en) * | 2023-01-30 | 2025-12-10 | Merck Sharp & Dohme LLC | Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors |
| US20250099464A1 (en) | 2023-09-27 | 2025-03-27 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical compositions |
| AU2023466962A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DE60005502T2 (de) | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
| WO2002074769A1 (en) | 2001-03-19 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| AU2011305652B2 (en) | 2010-09-22 | 2016-10-20 | Janssen Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| UY34372A (es) | 2011-10-06 | 2013-05-31 | Dow Agrosciences Llc | Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros. |
| KR102072041B1 (ko) | 2011-12-22 | 2020-01-31 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체 |
| SI2827875T1 (sl) | 2012-03-21 | 2019-04-30 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| CN105829333A (zh) | 2013-10-11 | 2016-08-03 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US9603864B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610597QA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2016057866A1 (en) | 2014-10-09 | 2016-04-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| CN107074899A (zh) * | 2014-10-31 | 2017-08-18 | 桑多斯股份公司 | 改进的氟化工艺 |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| JP6768796B2 (ja) * | 2015-09-23 | 2020-10-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製 |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| JP7160466B2 (ja) | 2016-06-23 | 2022-10-25 | ヴィーブ ヘルスケア カンパニー | 治療薬の送達のための組成物及び方法 |
| WO2018085307A1 (en) | 2016-11-03 | 2018-05-11 | Wu Laurence I | Prodrugs of clofarabine |
| US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| WO2019171285A1 (en) * | 2018-03-07 | 2019-09-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| CA3096400A1 (en) | 2018-04-09 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Certain pladienolide compounds and methods of use |
| MA53280A (fr) | 2018-08-09 | 2021-11-17 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| US20210323993A1 (en) | 2018-08-30 | 2021-10-21 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compounds Useful in HIV Therapy |
| US12018435B2 (en) | 2019-03-06 | 2024-06-25 | Chemstone, Inc. | Liquid dispersions for acyl halides |
-
2020
- 2020-03-04 PH PH1/2021/500034A patent/PH12021500034A1/en unknown
- 2020-03-04 SG SG11202109253SA patent/SG11202109253SA/en unknown
- 2020-03-04 CN CN202080030422.7A patent/CN113811360A/zh active Pending
- 2020-03-04 CA CA3132112A patent/CA3132112A1/en active Pending
- 2020-03-04 TW TW109107136A patent/TW202102233A/zh unknown
- 2020-03-04 MX MX2021010700A patent/MX2021010700A/es unknown
- 2020-03-04 BR BR112021017604A patent/BR112021017604A2/pt not_active IP Right Cessation
- 2020-03-04 EA EA202192433A patent/EA202192433A1/ru unknown
- 2020-03-04 CR CR20210460A patent/CR20210460A/es unknown
- 2020-03-04 MA MA055200A patent/MA55200A/fr unknown
- 2020-03-04 WO PCT/IB2020/051878 patent/WO2020178767A1/en not_active Ceased
- 2020-03-04 EP EP20712038.7A patent/EP3934760A1/en active Pending
- 2020-03-04 AU AU2020231934A patent/AU2020231934B2/en not_active Ceased
- 2020-03-04 JP JP2021552772A patent/JP2022525013A/ja not_active Ceased
- 2020-03-04 PE PE2021001461A patent/PE20212089A1/es unknown
- 2020-03-04 KR KR1020217031465A patent/KR20210136052A/ko not_active Withdrawn
- 2020-03-04 AR ARP200100588A patent/AR118240A1/es not_active Application Discontinuation
- 2020-05-04 US US16/865,678 patent/US12240853B2/en active Active
-
2021
- 2021-06-01 US US17/335,145 patent/US20220411425A1/en not_active Abandoned
- 2021-08-24 ZA ZA2021/06096A patent/ZA202106096B/en unknown
- 2021-08-26 IL IL285894A patent/IL285894A/en unknown
- 2021-09-03 CL CL2021002309A patent/CL2021002309A1/es unknown
- 2021-09-24 CO CONC2021/0012579A patent/CO2021012579A2/es unknown
-
2023
- 2023-11-14 US US18/508,355 patent/US20240182473A1/en not_active Abandoned
-
2025
- 2025-02-12 US US19/051,307 patent/US20260035371A1/en active Pending